Vaccitech $75 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
New Energy One Acquisition £175 million IPO
Shares of the SPAC are listed on the London Stock Exchange
LivaNova $345 million equity offering
We advised the underwriters on the SEC-registered offering
Royalty Pharma $1.3 billion senior notes offering
We advised Royalty Pharma on its SEC-registered investment-grade notes offering, including $600 million in social bonds
Sixjoy Hong Kong £919 million offer for Sumo Group
We are advising Tencent on the recommended cash offer by its indirect subsidiary
Membership Collective Group $420 million IPO
We advised the underwriters on the IPO and NYSE listing
Vaccitech $110.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Immunocore $297 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Abcam $180 million U.S. IPO of ADSs
Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…
Royalty Pharma $728 million secondary offering
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…